Wrap Text
ASPI hosts inaugural capital markets day and provides operational update
ASP ISOTOPES INC.
(Incorporated in the State of Delaware,
United States of America)
(Delaware file number 6228898)
Ticker Symbol: NASDAQ: ASPI
ISIN: US00218A1051
LEI: 6488WHV94BZ496OZ3219
JSE Share Code: ISO
("ASPI" or "the Company")
ASPI HOSTS INAUGURAL CAPITAL MARKETS DAY AND PROVIDES OPERATIONAL UPDATE
DALLAS, Sept. 08, 2026 (GLOBE NEWSWIRE) — ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes" or the
"Company"), an advanced materials company focused on developing technologies and processes for critical
materials production, today hosts its inaugural Capital Markets Day in London. Management will outline the
Company's strategy across nuclear medicine, electronics, helium and LNG, and nuclear fuels, and will provide an
overview of the building blocks supporting the Company’s long-term growth potential.
Over the past 12 months, the Company has moved from development into early commercialization across several of
its businesses. At today's event, management intends to provide a summary of what has been achieved to date,
target milestones for the next 12 months, and how the complementary businesses are building a pathway toward the
Company's longer-term EBITDA goal. The presentation builds on the Company’s shareholder letter published on
dated August 4, 2026 (here)
Paul Mann, Executive Chairman and Chief Executive Officer of ASP Isotopes, said:
"2026 is the year we are transitioning from building to producing. We have made steady progress towards the
targets we have set out publicly. Over the next 12 months, we expect to further advance in two meaningful
ways. First, increasing our revenues—from the expected production of liquid helium as Phase 1 is completed
and the continued growth of our radiopharmacies. Second, growing our customer base—as we expect to make
our first commercial shipments from our stable isotope division. Each of these is a step toward the more than
$300 million of EBITDA that we are targeting in 2031. In addition, we are continuing to pursue public listings of
Quantum Leap Energy and Noble Africa as separate public companies.
Operational Update
Detailed updates on each business are being presented today and are set out in the accompanying presentation
materials, available at https://ir.aspisotopes.com/news-events.
Webcast and Presentation Materials
The Capital Markets Day presentation and formal Q&A will take place from 10:00 a.m. to 12:30 p.m. ET (3:00 p.m.
to 5:30 p.m. BST) on Tuesday, September 8, 2026. A live webcast is available to the public and may be accessed
here. Presentation materials are available at https://ir.aspisotopes.com/news-events from the start of the webcast,
and a replay will be posted following the event.
About ASP Isotopes Inc.
ASP Isotopes is developing a differentiated isotope enrichment platform to strengthen global supply chain access to
critical materials used in nuclear medicine, next-generation semiconductors, and nuclear energy. The Company’s
proprietary technologies, the Aerodynamic Separation Process (“ASP technology”) and Quantum Enrichment (“QE
technology”), are designed to enable the production of isotopes for a range of industrial and advanced technology
applications. ASP Isotopes operates isotope enrichment facilities in Pretoria, South Africa, focused on the enrichment
of low atomic mass elements, or light isotopes. For more information, please visit www.aspisotopes.com.
About Renergen
Renergen Limited, a subsidiary of ASP Isotopes Inc., is a company incorporated under the laws of the Republic of
South Africa whose principal asset is its 94.5% equity ownership in Tetra4 Proprietary Limited. Tetra4 Proprietary
Limited holds an onshore petroleum production right and engages in the production and liquefaction of natural gas
and the exploration and development of helium resources at the Virginia Gas Plant located in Free State Province,
South Africa.
About Quantum Leap Energy
Quantum Leap Energy is a development stage nuclear fuels company dedicated to advancing innovative technologies
and processes across critical segments of the nuclear fuel cycle. The company focuses on uranium conversion,
enrichment of uranium-235 for nuclear fuel production (HALEU, LEU+ and LEU), and isotopic separation of lithium-6
and lithium-7, as well as radioactive waste treatment technologies. Through exclusive global rights to proprietary
Aerodynamic Separation Process (ASP) and laser-based Quantum Enrichment (QE) technologies, Quantum Leap
Energy aims to address perceived gaps in the nuclear fuel supply chain for advanced nuclear reactors, small modular
reactors, and fusion systems. The company has established strategic partnerships or commercial initiatives and
relationships with industry leaders including TerraPower, Fermi America, and the South Africa Nuclear Energy
Corporation (Necsa) to accelerate the commercialization of critical isotopes essential for next-generation nuclear
energy systems. *The company has not applied its enrichment technologies to the enrichment of U-235, nor received
permission or regulatory approval to conduct testing of our enrichment technologies on U-235, except for the activities
contemplated by the services contract with Necsa. For additional information, please visit: https://www.qleapenergy.com/.
Important Additional Information and Where to Find It
In connection with the proposed merger and related transactions (the “Proposed Transactions”) involving ENDRA
Life Sciences Inc. (“ENDRA”), ASP Isotopes, Renergen, and Noble Africa LLC, a subsidiary of ASP Isotopes and
future holding company for Renergen (“Noble Africa”), ENDRA intends to file relevant materials with the U.S.
Securities and Exchange Commission (the “SEC”), including a registration statement on Form S-4 (the “Form S-4”),
that will contain a proxy statement (the “Proxy Statement”) and prospectus. This communication is not a substitute
for the Form S-4, the Proxy Statement or for any other document that ENDRA may file with the SEC and/or send to
its stockholders in connection with the Proposed Transactions. INVESTORS AND STOCKHOLDERS OF ENDRA
ARE URGED TO READ THE FORM S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS
THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE
DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE
THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ENDRA, ASP ISOTOPES, RENERGEN, NOBLE
AFRICA, THE PROPOSED TRANSACTIONS AND RELATED MATTERS. Investors and stockholders will be able to
obtain free copies of the Form S-4, the Proxy Statement and other documents filed by ENDRA and ASP Isotopes
with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. ENDRA’s
Internet website address is www.endrainc.com. ENDRA’s Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, Current Reports on Form 8-K, including exhibits, and amendments to those reports filed or furnished pursuant
to Section 13(a) or 15(d) of the Exchange Act are available free of charge through the investor relations page of its
Internet website as soon as reasonably practicable after it electronically files such material with, or furnishes such
material to, the SEC.
Participants in the Solicitation
ENDRA, ASP Isotopes, Renergen, Noble Africa, and their respective directors and managers and certain of their
executive officers and other members of management may be deemed to be participants in the solicitation of proxies
from ENDRA’s stockholders in connection with the Proposed Transactions under the rules of the SEC. Information
about ENDRA’s directors and executive officers, including a description of their interests in ENDRA, is included in
ENDRA’s most recent Annual Report on Form 10-K for the year ended December 31, 2025. Information about ASP
Isotopes’ directors and executive officers, including a description of their interests in ASP Isotopes, is included in ASP
Isotopes’ most recent Annual Report on Form 10-K for the year ended December 31, 2025. Additional information
regarding the persons who may be deemed participants in the proxy solicitations, including the directors and executive
officers of Renergen, and a description of their direct and indirect interests, by security holdings or otherwise, will also
be included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they
become available. These documents can be obtained free of charge from the sources indicated above.
No Offer or Solicitation
This press release is not intended to and does not constitute a solicitation of a proxy, consent or approval with respect
to any securities or in respect of the Proposed Transactions or an offer to sell or the solicitation of an offer to subscribe
for or buy or an invitation to purchase or subscribe for any securities pursuant to the Proposed Transactions or
otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of
applicable law. No offering of securities shall be made except by means of a prospectus meeting the requirements of
Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law, or an
exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be
ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would
constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality
(including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or
any facility of a national securities exchange, of any such jurisdiction.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions
regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the
economy, and other future conditions. Forward-looking statements can be identified by words such as “believes,”
“plans,” “anticipates,” “expects,” “estimates,” “projects,” “will,” “may,” “might,” and words of a similar nature. Examples
of forward-looking statements include, among others but are not limited to, statements we make regarding: the
anticipated production quantities and timing for the commencement of commercial supply of enriched isotopes to
customers; the construction of additional enrichment facilities; the expected growth of the radiopharmacy business;
the anticipated progress and timing for completion of Phase 1 and commencement of Phase 2 of the Virginia Gas
Project; the ability to fund completion of the development of the Virginia Gas Project (including the ability to negotiate
and enter into binding definitive agreements with the U.S. DFC and Standard Bank SA for senior debt funding for
Phase 2 of the Virginia Gas Project); the overall project scope, size, design and product mix of future phases of the
Virginia Gas Project; the anticipated production quantities and supply of helium and LNG upon completion of Phase
1 and 2 of the Virginia Gas Project; the impact of the conflict in the Middle East and the closure of the Strait of Hormuz
on the helium market; the completion of the Noble Africa reverse merger and private placement and other transactions
in the anticipated timeframe or at all; expectations regarding the structure, timing and completion of the Noble Africa
reverse merger, including investment amounts from investors, timing of closing of the Noble Africa reverse merge r,
expected proceeds, expectations regarding the use of proceeds, and impact on ownership structure; the Noble Africa
reverse merger and the expected effects, perceived benefits or opportunities of the Noble Africa reverse merger; the
combined company’s listing on Nasdaq after the closing of the Noble Africa reverse merger; the anticipated timing of
the closing of the Noble Africa reverse merger; the plans for QLE to be a standalone public company or for ASPI to
make a future distribution of QLE common equity to ASPI’s stockholders; the anticipated timing to advance drug
candidates towards human clinical trials and the plans to create a pipeline of VHH; the outcome of QLE’s initiative to
commence enrichment of uranium in South Africa and the company’s discussions with nuclear regulators in South
Africa, the United States or the United Kingdom; the outcome of QLE’s collaboration with The South African Nuclear
Energy Corporation (Necsa); the commencement of research, development and production activities in the United
States or the United Kingdom; QLE’s anticipated growth strategies and anticipated trends in QLE’s business;
statements relating to QLE’s strategic partnerships or commercial initiatives and relationships with Fermi America,
TerraPower and Necsa; the application of new technology for the enrichment of isotopes; the planned construction
of additional isotope enrichment facilities; and statements we make regarding expected operating results, such as
future revenues and prospects from the potential commercialization of enriched isotopes or helium and LNG, future
performance under contracts, and our strategies for product development or extraction of resources, engaging with
potential customers, market position, and financial results. Because forward-looking statements relate to the future,
they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, many of
which are outside our control. Our actual results, financial condition, and events may differ materially from those
indicated in the forward-looking statements based upon a number of factors. Forward-looking statements are not a
guarantee of future performance or developments. You are strongly cautioned that reliance on any forward -looking
statements involves known and unknown risks and uncertainties. Therefore, you should not rely on any of these
forward-looking statements.
There are many important factors that could cause our actual results and financial condition to differ materially from
those indicated in the forward-looking statements, including, but not limited to: the outcomes of various strategies and
projects undertaken by the Company; the potential impact of laws or government regulations or policies in South
Africa, the United Kingdom or elsewhere; our future capital requirements and sources and uses of cash; ou r ability to
obtain funding for our operations and future growth; our ability to negotiate and enter into binding definitive
agreements with U.S. DFC and Standard Bank SA for senior debt funding for Phase 2 of the Virginia Gas Project on
terms that are favorable, or at all; changes made by management to the overall project scope, size, design,
sequencing or product mix of future phases of the Virginia Gas Project following completion of management's pre -
development activities and plant design optimization processes; whether we succeed in obtaining permissions and
regulatory approvals required to test and develop our enrichment technologies on uranium in South Africa, the United
Kingdom or elsewhere; our reliance on the efforts of third parties; our ability to complete the proposed construction
and commissioning of our enrichment plant(s) or to commercialize isotopes using the ASP technology or the Quantum
Enrichment Process; our ability to obtain regulatory approvals for the production and distribution of iso topes; the
financial terms of any current and future commercial arrangements; our ability to complete certain transactions and
realize anticipated benefits from acquisitions; contracts, dependence on our Intellectual Property (IP) rights, certain
IP rights of third parties; the competitive nature of our industry; risks related to the consummation of the proposed
reverse merger of Noble Africa with ENDRA Life Sciences in the anticipated timeframe, if at all; the failure to obtain
necessary regulatory approvals and third party consents; if consummated, the ability to realize the anticipated benefits
of the proposed reverse merger of Noble Africa with ENDRA; the ability to successfully integrate the businesses;
disruption from the proposed reverse merger of Noble Africa with ENDRA making it more difficult to maintain business
and operational relationships; the negative effects of the consummation of the proposed reverse merger of Noble
Africa with ENDRA on the market price of Noble Africa’s or ASPI’s securities; the risk that the proposed financings
are not completed in a timely manner, if at all; risks related to ENDRA’s continued listing on Nasdaq until closing of
the proposed reverse merger and the combined company’s ability to remain listed following the closing of the reverse
merger; significant transaction costs and unknown liabilities, and litigation or regulatory actions related to the
proposed reverse merger of Noble Africa with ENDRA; and the factors disclosed in Part I, Item 1A. “Risk Factors” of
the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and any subsequent Quarterly
Reports on Form 10-Q filed with the Securities and Exchange Commission. Any forward-looking statement made by
us in this press release is based only on information currently available to us and speaks only as of the date on which
it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new
information, future developments or otherwise. All forward-looking statements herein are qualified by reference to the
cautionary statements set forth herein and should not be relied upon.
Use of Projections
The financial outlook and projections, estimates and targets in this press release are forward-looking statements that
are based on assumptions that are inherently subject to significant uncertainty and contingencies, many of which are
beyond ASP Isotopes’ control. Any such calculation, at this time, would imply a degree of precision that could be
confusing or misleading to investors. Neither ASP Isotopes nor Renergen’s independent auditors have audited,
reviewed, compiled or performed any procedures with respect to the financial projections for purposes of inclusion in
this press release, and, accordingly, they did not express an opinion or provide any other form of assurance with
respect thereto for the purposes of this press release. While all financial projections, estimates and targets are
necessarily speculative, ASP Isotopes believes that the preparation of prospective financial information involves
increasingly higher levels of uncertainty the further out the projection, estimate or target extends from the date of
preparation. The assumptions and estimates underlying the projected, expected or target results for ASP Isotopes
and its subsidiaries are inherently uncertain and are subject to a wide variety of significant business, economic and
competitive risks and uncertainties that could cause actual results to differ materially from those contained in the
financial projections, estimates and targets. The inclusion of financial projections, estimates and targets in this press
release should not be regarded as an indication that ASP Isotopes, or its representatives, considered or consider the
financial projections, estimates or targets to be a reliable prediction of future events. Further, inclusion of the
prospective financial information in this press release should not be regarded as a representation by any person that
the results contained in the prospective financial information will be achieved.
Non-GAAP Financial Measure
EBITDA is a non-GAAP financial measure and is defined as net income before interest, taxes, depreciation and
amortization. We have not provided a reconciliation between our targets for EBITDA and net income(loss), the most
directly comparable GAAP measure, because applicable information for future periods, on which this reconciliation
would be based, is not available without unreasonable effort due to the unavailability of reliable estimates for selling
prices of our commercial products and costs of production and extraction, among other items. These items may vary
greatly between periods and could significantly impact future financial results.
Contact
IR@ASPIsotopes.com
The Company has a primary listing on the Nasdaq and a secondary listing on the Main Board of the JSE.
8 September 2026
Sponsor
Valeo Capital Proprietary Limited
Date: 08/09/2026 03:15:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
